Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Tuberculosis

  Free Subscription


Articles published in Eur Respir J

Retrieve available abstracts of 215 articles:
HTML format
Text format



Single Articles


    June 2018
  1. GUGLIELMETTI L, Tiberi S, Burman M, Kunst H, et al
    QT prolongation and cardiac toxicity of new tuberculosis drugs in Europe: A Tuberculosis Network European Trialsgroup (TBnet) study.
    Eur Respir J. 2018 Jun 7. pii: 13993003.00537-2018.
    PubMed     Text format    


    May 2018
  2. DOBLER CC, Fox GJ, Douglas P, Viney KA, et al
    Screening for tuberculosis in migrants and visitors from high incidence settings: present and future perspectives.
    Eur Respir J. 2018 May 24. pii: 13993003.00591-2018.
    PubMed     Text format     Abstract available


  3. ASSEFA Y, Assefa Y, Woldeyohannes S, Hamada Y, et al
    Three-month daily Rifampicin and Isoniazid compared to six or nine-month Isoniazid for treating latent tuberculosis infection in children and adolescents less than 15 years of age: an updated systematic review.
    Eur Respir J. 2018 May 10. pii: 13993003.00395-2018.
    PubMed     Text format    


  4. MOHR E, Hughes J, Reuter A, Trivino Duran L, et al
    Delamanid for Rifampicin-Resistant Tuberculosis: A Retrospective Study from South Africa.
    Eur Respir J. 2018 May 3. pii: 13993003.00017-2018.
    PubMed     Text format     Abstract available


  5. MUSTAZZOLU A, Borroni E, Maria Cirillo D, Giannoni F, et al
    Trend of rifampicin resistant, MDR and XDR tuberculosis in Italy, 2009-2016.
    Eur Respir J. 2018 May 3. pii: 13993003.00070-2018.
    PubMed     Text format    


  6. ABUBAKAR I, Matteelli A, de Vries G, Zenner D, et al
    Towards tackling tuberculosis in vulnerable groups in the European Union: the E-DETECT TB consortium.
    Eur Respir J. 2018;51.
    PubMed     Text format    


  7. VILLANUEVA P, Neth O, Ritz N, Tebruegge M, et al
    Use of Xpert MTB/RIF Ultra assays among paediatric tuberculosis experts in Europe.
    Eur Respir J. 2018;51.
    PubMed     Text format    



  8. "Low prevalence of fluoroquinolone resistance among patients with tuberculosis in the Philippines: results of a national survey." Dodge R. Lim, Anna S. Dean, Mary Rosary Taguinod-Santiago, Angeli Borbe-Reyes, Andrea Maurizio Cabibbe, Matteo Zignol, Ra
    Eur Respir J. 2018;51.
    PubMed     Text format    


    April 2018
  9. OLAYANJU O, Limberis J, Esmail A, Oelofse S, et al
    LONG TERM BEDAQUILINE-RELATED TREATMENT OUTCOMES IN PATIENTS WITH EXTENSIVELY DRUG RESISTANT TUBERCULOSIS FROM SOUTH AFRICA.
    Eur Respir J. 2018 Apr 26. pii: 13993003.00544-2018.
    PubMed     Text format    


  10. MIGLIORI GB, Sotgiu G, Rosales-Klintz S, Centis R, et al
    ERS/ECDC Statement: European Union Standards for Tuberculosis Care - 2017 update.
    Eur Respir J. 2018 Apr 20. pii: 13993003.02678-2017.
    PubMed     Text format     Abstract available


  11. CABIBBE AM, Trovato A, De Filippo MR, Ghodousi A, et al
    Countrywide implementation of whole genome sequencing: an opportunity to improve tuberculosis management, surveillance and contact tracing in low incidence countries.
    Eur Respir J. 2018 Apr 12. pii: 13993003.00387-2018.
    PubMed     Text format    


  12. CHANG KC, Chung-Ching Leung E, Law WS, Leung WM, et al
    Early experience with delamanid-containing regimens in the treatment of complicated multidrug-resistant tuberculosis in Hong Kong.
    Eur Respir J. 2018 Apr 12. pii: 13993003.00159-2018.
    PubMed     Text format    


    March 2018
  13. LYLES G, Ogarkov O, Zhdanova S, Peloquin CA, et al
    Pharmacokinetics of tuberculosis drugs in HIV infected patients from Irkutsk, Russian Federation: redefining drug activity.
    Eur Respir J. 2018 Mar 29. pii: 13993003.00109-2018.
    PubMed     Text format    


  14. JAFARI C, Olaru ID, Daduna F, Ernst M, et al
    Rapid diagnosis of pulmonary tuberculosis by combined molecular and immunological methods.
    Eur Respir J. 2018 Mar 29. pii: 13993003.02189-2017.
    PubMed     Text format     Abstract available


  15. LIM DR, Dean AS, Taguinod-Santiago MR, Borbe-Reyes A, et al
    Low prevalence of fluoroquinolone resistance among patients with tuberculosis in the Philippines: results of a national survey.
    Eur Respir J. 2018 Mar 1. pii: 13993003.02571-2017.
    PubMed     Text format    


  16. KIM CT, Kim TO, Shin HJ, Ko YC, et al
    Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea.
    Eur Respir J. 2018;51.
    PubMed     Text format     Abstract available


  17. SAUNDERS MJ, Tovar MA, Datta S, Evans BEW, et al
    Pragmatic tuberculosis prevention policies for primary care in low- and middle-income countries.
    Eur Respir J. 2018;51.
    PubMed     Text format    


  18. RUDGARD WE, das Chagas NS, Gayoso R, Barreto ML, et al
    Uptake of governmental social protection and financial hardship during drug-resistant tuberculosis treatment in Rio de Janeiro, Brazil.
    Eur Respir J. 2018;51.
    PubMed     Text format    


  19. MUSVOSVI M, Duffy D, Filander E, Africa H, et al
    T-cell biomarkers for diagnosis of tuberculosis: candidate evaluation by a simple whole blood assay for clinical translation.
    Eur Respir J. 2018;51.
    PubMed     Text format    


  20. GILPIN C, Korobitsyn A, Migliori GB, Raviglione MC, et al
    The World Health Organization standards for tuberculosis care and management.
    Eur Respir J. 2018;51.
    PubMed     Text format    


  21. DE VRIES G, van den Hof S, Op de Coul E, van Crevel R, et al
    Closing the gap in surveillance of tuberculosis and HIV co-infection, and the need for clinician-public health alliances.
    Eur Respir J. 2018;51.
    PubMed     Text format    


  22. MUNOZ-TORRICO M, Salazar MA, Millan MJM, Martinez Orozco JA, et al
    Eligibility for the shorter regimen for multidrug-resistant tuberculosis in Mexico.
    Eur Respir J. 2018;51.
    PubMed     Text format    


  23. TIBERI S, Payen MC, Sotgiu G, D'Ambrosio L, et al
    Renal Fanconi syndrome with meropenem-containing regimen in drug-resistant tuberculosis.
    Eur Respir J. 2018;51.
    PubMed     Text format    


  24. HALLEUX CM, Falzon D, Merle C, Jaramillo E, et al
    The World Health Organization global aDSM database: generating evidence on the safety of new treatment regimens for drug-resistant tuberculosis.
    Eur Respir J. 2018;51.
    PubMed     Text format    


    February 2018
  25. SULIS G, Agliati A, Pinsi G, Bozzola G, et al
    Xpert MTB/RIF as add-on test to microscopy in a low tuberculosis incidence setting.
    Eur Respir J. 2018 Feb 8. pii: 13993003.02345-2017.
    PubMed     Text format    


  26. AKKERMAN OW, Grasmeijer F, de Lange WCM, Kerstjens HAM, et al
    Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis.
    Eur Respir J. 2018 Feb 1. pii: 13993003.02490-2017.
    PubMed     Text format    


  27. CHIANG CY, Trebucq A
    Tuberculosis re-treatment after exclusion of rifampicin resistance.
    Eur Respir J. 2018;51.
    PubMed     Text format    


  28. KEMPKER RR, Heinrichs MT, Nikolaishvili K, Sabulua I, et al
    A comparison of linezolid lung tissue concentrations among patients with drug-resistant tuberculosis.
    Eur Respir J. 2018;51.
    PubMed     Text format    


  29. JOHNSTON JC, van der Kop ML, Smillie K, Ogilvie G, et al
    The effect of text messaging on latent tuberculosis treatment adherence: a randomised controlled trial.
    Eur Respir J. 2018;51.
    PubMed     Text format     Abstract available


  30. GARCIA-BASTEIRO AL, Schaaf HS, Diel R, Migliori GB, et al
    Adolescents and young adults: a neglected population group for tuberculosis surveillance.
    Eur Respir J. 2018;51.
    PubMed     Text format    


  31. ALVAREZ-URIA G, Midde M
    Sex differences and factors influencing the duration of the QT interval in patients on anti-tuberculosis therapy.
    Eur Respir J. 2018;51.
    PubMed     Text format    


  32. SNOW KJ, Sismanidis C, Denholm J, Sawyer SM, et al
    The incidence of tuberculosis among adolescents and young adults: a global estimate.
    Eur Respir J. 2018;51.
    PubMed     Text format     Abstract available


  33. HEYCKENDORF J, van Leth F, Kalsdorf B, Olaru ID, et al
    Relapse-free cure from multidrug-resistant tuberculosis in Germany.
    Eur Respir J. 2018;51.
    PubMed     Text format    


    January 2018
  34. HEYSELL SK, Ahmed S, Rahman MT, Akhanda MW, et al
    Hearing loss with Kanamycin treatment for multidrug-resistant tuberculosis in Bangladesh.
    Eur Respir J. 2018 Jan 18. pii: 13993003.01778-2017.
    PubMed     Text format    


  35. ACUNA-VILLAORDUNA C, Jones-Lopez EC, Fregona G, Marques-Rodrigues P, et al
    Intensity of exposure to pulmonary tuberculosis determines risk of tuberculosis infection and disease.
    Eur Respir J. 2018;51.
    PubMed     Text format     Abstract available


  36. NGWATU BK, Nsengiyumva NP, Oxlade O, Mappin-Kasirer B, et al
    The impact of digital health technologies on tuberculosis treatment: a systematic review.
    Eur Respir J. 2018;51.
    PubMed     Text format     Abstract available


  37. LOUTET MG, Burman M, Jayasekera N, Trathen D, et al
    National roll-out of latent tuberculosis testing and treatment for new migrants in England: a retrospective evaluation in a high-incidence area.
    Eur Respir J. 2018;51.
    PubMed     Text format     Abstract available


  38. AL YAQUOBI F, Al-Abri S, Al-Abri B, Al-Abaidani I, et al
    Tuberculosis elimination: a dream or a reality? The case of Oman.
    Eur Respir J. 2018;51.
    PubMed     Text format    


  39. VAN DEN ELSEN SHJ, Akkerman OW, Huisman JR, Touw DJ, et al
    Lack of penetration of amikacin into saliva of tuberculosis patients.
    Eur Respir J. 2018;51.
    PubMed     Text format    


  40. PADRAO E, Oliveira O, Felgueiras O, Gaio AR, et al
    Tuberculosis and tobacco: is there any epidemiological association?
    Eur Respir J. 2018;51.
    PubMed     Text format    


    December 2017
  41. CHE Y, Song Q, Yang T, Ping G, et al
    Fluoroquinolone resistance in multidrug-resistant Mycobacterium tuberculosis independent of fluoroquinolone use.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  42. CABIBBE AM, Sotgiu G, Izco S, Migliori GB, et al
    Genotypic and phenotypic M. tuberculosis resistance: guiding clinicians to prescribe the correct regimens.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  43. ABADIE ME, Strich JR, Kim T, Xie YL, et al
    Renal Fanconi syndrome with meropenem/amoxicillin-clavulanate during treatment of extensively drug-resistant tuberculosis.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  44. MIOTTO P, Tessema B, Tagliani E, Chindelevitch L, et al
    A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis.
    Eur Respir J. 2017;50.
    PubMed     Text format     Abstract available


    November 2017
  45. LUZZATI R, Migliori GB, Zignol M, Cirillo DM, et al
    Children under 5 years are at risk for tuberculosis after occasional contact with highly contagious patients: outbreak from a smear-positive healthcare worker.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  46. FALZON D, Migliori GB, Jaramillo E, Weyer K, et al
    Digital health to end tuberculosis in the Sustainable Development Goals era: achievements, evidence and future perspectives.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  47. FURIN J, Lessem E, Cox V
    Recommending prolonged bedaquiline use for the treatment of highly resistant strains of tuberculosis.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  48. KUKSA L, Barkane L, Hittel N, Gupta R, et al
    Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  49. VAN DER WERF MJ, Sotgiu G, Dara M
    Closing the gap in surveillance of tuberculosis and HIV co-infection: a European perspective on the need for clinician-public health alliances.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  50. ARNOLDUSSEN M, Schimmel H, Op de Coul E, van den Hof S, et al
    Tuberculosis patients with unknown HIV status in the Netherlands: analysing underreporting and lack of testing.
    Eur Respir J. 2017;50.
    PubMed     Text format    


    October 2017
  51. VAN DE BERG S, Erkens C, van Rest J, van den Hof S, et al
    Evaluation of tuberculosis screening of immigrants in the Netherlands.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  52. HELDAL E
    A katG 315 mutation alone should not lead to exclusion of isoniazid in treatment of multidrug-resistant tuberculosis.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  53. CHESOV D, Ciobanu N, Lange C, Heyckendorf J, et al
    High-dose isoniazid in the shorter-course multidrug-resistant tuberculosis regimen in the Republic of Moldova.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  54. KODAMA C, Lange B, Olaru ID, Khan P, et al
    Mycobacterium tuberculosis transmission from patients with drug-resistant compared to drug-susceptible TB: a systematic review and meta-analysis.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  55. FIEBIG L, Hauer B, Andres M, Haas W, et al
    Tuberculosis screening in asylum seekers in Germany, 2015: characteristics of cases and yield.
    Eur Respir J. 2017;50.
    PubMed     Text format    


    September 2017
  56. FOURNIER A, Bernard C, Sougakoff W, Quelet S, et al
    Neither genotyping nor contact tracing allow correct understanding of multidrug-resistant tuberculosis transmission.
    Eur Respir J. 2017;50.
    PubMed     Text format    


    August 2017
  57. CHEE CBE, KhinMar KW, Sng LH, Jureen R, et al
    The shorter multidrug-resistant tuberculosis treatment regimen in Singapore: are patients from South-East Asia eligible?
    Eur Respir J. 2017;50.
    PubMed     Text format    


  58. CAZABON D, Suresh A, Oghor C, Qin ZZ, et al
    Implementation of Xpert MTB/RIF in 22 high tuberculosis burden countries: are we making progress?
    Eur Respir J. 2017;50.
    PubMed     Text format    


  59. LEE MR, Ho CM, Lee CH, Lee MC, et al
    Tuberculosis contact investigation in an intermediate burden setting: implications from a large tuberculosis contact cohort in Taiwan.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  60. DOBLER CC, Cheung K, Nguyen J, Martin A, et al
    Risk of tuberculosis in patients with solid cancers and haematological malignancies: a systematic review and meta-analysis.
    Eur Respir J. 2017;50.
    PubMed     Text format     Abstract available


    July 2017
  61. CAMINERO JA, Piubello A, Scardigli A, Migliori GB, et al
    Proposal for a standardised treatment regimen to manage pre- and extensively drug-resistant tuberculosis cases.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  62. AHMAD KHAN F, Pande T, Tessema B, Song R, et al
    Computer-aided reading of tuberculosis chest radiography: moving the research agenda forward to inform policy.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  63. RAVIGLIONE M, Poznyak V
    Targeting harmful use of alcohol for prevention and treatment of tuberculosis: a call for action.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  64. IMTIAZ S, Shield KD, Roerecke M, Samokhvalov AV, et al
    Alcohol consumption as a risk factor for tuberculosis: meta-analyses and burden of disease.
    Eur Respir J. 2017;50.
    PubMed     Text format     Abstract available


  65. AHMAD KHAN F, Salim MAH, du Cros P, Casas EC, et al
    Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses.
    Eur Respir J. 2017;50.
    PubMed     Text format     Abstract available


  66. ZENNER D, Loutet MG, Harris R, Wilson S, et al
    Evaluating 17 years of latent tuberculosis infection screening in north-west England: a retrospective cohort study of reactivation.
    Eur Respir J. 2017;50.
    PubMed     Text format     Abstract available


  67. GUGLIELMETTI L, Varaine F, Huerga H, Bonnet M, et al
    Shortened multidrug-resistant tuberculosis treatment in settings with a high prevalence of ofloxacin resistance.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  68. ONI T, Berkowitz N, Kubjane M, Goliath R, et al
    Trilateral overlap of tuberculosis, diabetes and HIV-1 in a high-burden African setting: implications for TB control.
    Eur Respir J. 2017;50.
    PubMed     Text format     Abstract available


  69. MULLERPATTAN JB, Nikam C, Sharma U, Rodrigues C, et al
    Rifampicin-resistant tuberculosis: what is the best initial empiric regimen in Mumbai, India?
    Eur Respir J. 2017;50.
    PubMed     Text format    


    June 2017
  70. SOLOVIC I, Abubakar I, Sotgiu G, Dara M, et al
    Standard operating procedures for tuberculosis care.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  71. VAN DER WERF MJ, Kodmon C, Catchpole M
    Shorter regimens for multidrug-resistant tuberculosis should also be applicable in Europe.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  72. HELDAL E, Van Deun A, Chiang CY, Rieder HL, et al
    Shorter regimens for multidrug-resistant tuberculosis should also be applicable in Europe.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  73. VAN DEUN A, Chiang CY
    Shortened multidrug-resistant tuberculosis regimens overcome low-level fluoroquinolone resistance.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  74. BOERE TM, Visser DH, van Furth AM, Lips P, et al
    Solar ultraviolet B exposure and global variation in tuberculosis incidence: an ecological analysis.
    Eur Respir J. 2017;49.
    PubMed     Text format     Abstract available


    May 2017
  75. OLARU ID, Heyckendorf J, Andres S, Kalsdorf B, et al
    Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  76. GUGLIELMETTI L
    Bedaquiline for the treatment of multidrug-resistant tuberculosis: another missed opportunity?
    Eur Respir J. 2017;49.
    PubMed     Text format    


  77. MILLER C, Lonnroth K, Sotgiu G, Migliori GB, et al
    The long and winding road of chest radiography for tuberculosis detection.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  78. RAHMAN MT, Codlin AJ, Rahman MM, Nahar A, et al
    An evaluation of automated chest radiography reading software for tuberculosis screening among public- and private-sector patients.
    Eur Respir J. 2017;49.
    PubMed     Text format     Abstract available


    April 2017
  79. CATANZARO DG, Trollip AP, Seifert M, Georghiou SB, et al
    Evaluation of the microscopic observation drug susceptibility assay for the detection of first- and second-line drug susceptibility for Mycobacterium tuberculosis.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  80. DALCOLMO M, Gayoso R, Sotgiu G, D'Ambrosio L, et al
    Resistance profile of drugs composing the "shorter" regimen for multidrug-resistant tuberculosis in Brazil, 2000-2015.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  81. NAKIWALA D, Kellgren L, Herzmann C, Olaru ID, et al
    Language discordance between tuberculosis patients and healthcare providers challenging universal access.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  82. BOZORGMEHR K, Joggerst B, Wagner U, Stock C, et al
    Yield of tuberculosis screening in asylum-seekers by country of origin: analysis of screening data in a German federal state (2002-2015).
    Eur Respir J. 2017;49.
    PubMed     Text format    


  83. FALZON D, Jaramillo E, Gilpin C, Weyer K, et al
    Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  84. DAVIES FORSMAN L, Bruchfeld J, Alffenaar JC
    Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis.
    Eur Respir J. 2017;49.
    PubMed     Text format    


    March 2017
  85. PONTALI E, D'Ambrosio L, Centis R, Sotgiu G, et al
    Multidrug-resistant tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  86. YASSIN MA, Jaramillo E, Wandwalo E, Falzon D, et al
    Investing in a novel shorter treatment regimen for multidrug-resistant tuberculosis: to be repeated.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  87. DALCOLMO M, Gayoso R, Sotgiu G, D'Ambrosio L, et al
    Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil.
    Eur Respir J. 2017;49.
    PubMed     Text format     Abstract available


  88. FALZON D, Schunemann HJ, Harausz E, Gonzalez-Angulo L, et al
    World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update.
    Eur Respir J. 2017;49.
    PubMed     Text format     Abstract available


  89. SINKOU H, Hurevich H, Rusovich V, Zhylevich L, et al
    Video-observed treatment for tuberculosis patients in Belarus: findings from the first programmatic experience.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  90. VAN DER WERF MJ, Hollo V, Kodmon C, Dara M, et al
    Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  91. KAMADA A, Amishima M
    QuantiFERON-TB(R) Gold Plus as a potential tuberculosis treatment monitoring tool.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  92. BJORN-MORTENSEN K, Lillebaek T, Koch A, Soborg B, et al
    Extent of transmission captured by contact tracing in a tuberculosis high endemic setting.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  93. VAN KAMPENHOUT E, Bolhuis MS, Alffenaar JC, Oswald LM, et al
    Pharmacokinetics of moxifloxacin and linezolid during and after pregnancy in a patient with multidrug-resistant tuberculosis.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  94. UDWADIA ZF, Ganatra S, Mullerpattan JB
    Compassionate use of bedaquiline in highly drug-resistant tuberculosis patients in Mumbai, India.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  95. GARCIA-BASTEIRO AL, Miranda Ribeiro R, Brew J, Sacoor C, et al
    Tuberculosis on the rise in southern Mozambique (1997-2012).
    Eur Respir J. 2017;49.
    PubMed     Text format    


  96. VAN DER PAARDT AL, Akkerman OW, Gualano G, Palmieri F, et al
    Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  97. LU P, Liu Q, Martinez L, Yang H, et al
    Time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis: a prospective cohort study from urban China.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  98. ROTH DZ, Ronald LA, Ling D, Chiang LY, et al
    Impact of interferon-gamma release assay on the latent tuberculosis cascade of care: a population-based study.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  99. BASTOS ML, Lan Z, Menzies D
    An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis.
    Eur Respir J. 2017;49.
    PubMed     Text format     Abstract available


    February 2017
  100. BLASI F, Matteelli A, Sotgiu G, Cirillo DM, et al
    Moving towards tuberculosis elimination: a call for action from Italy and a possible model for other low tuberculosis incidence countries.
    Eur Respir J. 2017;49.
    PubMed     Text format    


    January 2017
  101. SOTGIU G, Migliori GB
    Group 5 drugs for multidrug-resistant tuberculosis: is the glass half full or half empty?
    Eur Respir J. 2017;49.
    PubMed     Text format    


  102. JAVAID A, Ahmad N, Khan AH, Shaheen Z, et al
    Applicability of the World Health Organization recommended new shorter regimen in a multidrug-resistant tuberculosis high burden country.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  103. FOX GJ, Benedetti A, Cox H, Koh WJ, et al
    Group 5 drugs for multidrug-resistant tuberculosis: individual patient data meta-analysis.
    Eur Respir J. 2017;49.
    PubMed     Text format     Abstract available


  104. IZCO S, Eyene J, Perez-Lago L, Herranz M, et al
    Equatorial Guinea, a multidrug-resistant tuberculosis hotspot in Central Africa.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  105. FRANCISCO J, Oliveira O, Felgueiras O, Gaio AR, et al
    How much is too much alcohol in tuberculosis?
    Eur Respir J. 2017;49.
    PubMed     Text format    


  106. NATHAVITHARANA RR, Cudahy PG, Schumacher SG, Steingart KR, et al
    Accuracy of line probe assays for the diagnosis of pulmonary and multidrug-resistant tuberculosis: a systematic review and meta-analysis.
    Eur Respir J. 2017;49.
    PubMed     Text format     Abstract available



  107. "Monitoring latent tuberculosis infection diagnosis and management in the Netherlands." Connie G.M. Erkens, Erika Slump, Maurits Verhagen, Henrieke Schimmel, Gerard de Vries, Frank Cobelens and Susan van den Hof. Eur Respir J 2016; 47: 1492-1501.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  108. LIENHARDT C, Nahid P, Rich ML, Bansbach C, et al
    Target regimen profiles for treatment of tuberculosis: a WHO document.
    Eur Respir J. 2017;49.
    PubMed     Text format    


    December 2016
  109. PEDRAZZOLI D, Lalli M, Boccia D, Houben R, et al
    Can tuberculosis patients in resource-constrained settings afford chest radiography?
    Eur Respir J. 2016 Dec 23. pii: 1601877. doi: 10.1183/13993003.01877-2016.
    PubMed     Text format    


  110. GUGLIELMETTI L, Jaspard M, Le Du D, Lachatre M, et al
    Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis.
    Eur Respir J. 2016 Dec 22. pii: 1601799. doi: 10.1183/13993003.01799-2016.
    PubMed     Text format     Abstract available


  111. VEZIRIS N, Bernard C, Guglielmetti L, Le Du D, et al
    Rapid emergence of Mycobacterium tuberculosis bedaquiline resistance: lessons to avoid repeating past errors.
    Eur Respir J. 2016 Dec 22. pii: 1601719. doi: 10.1183/13993003.01719-2016.
    PubMed     Text format    


    November 2016
  112. PETRUCCIOLI E, Scriba TJ, Petrone L, Hatherill M, et al
    Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis.
    Eur Respir J. 2016 Nov 11. pii: ERJ-01012-2016. doi: 10.1183/13993003.01012-2016
    PubMed     Text format     Abstract available


  113. ALBERT H, Nathavitharana RR, Denkinger CM, Isaacs C, et al
    Tuberculosis prevention must integrate technological and basic care innovation.
    Eur Respir J. 2016;48:1531-1532.
    PubMed     Text format    


  114. MASON PH, Oni T, van Herpen MM, Coussens AK, et al
    Tuberculosis prevention must integrate technological and basic care innovation.
    Eur Respir J. 2016;48:1529-1531.
    PubMed     Text format    


  115. TADOLINI M, Lingtsang RD, Tiberi S, Enwerem M, et al
    Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine.
    Eur Respir J. 2016;48:1527-1529.
    PubMed     Text format    


  116. WALLIS RS
    Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine.
    Eur Respir J. 2016;48:1526-1527.
    PubMed     Text format    


  117. PILARSKI A, Penn N, Ratnakumar S, Barker RD, et al
    Variation in vitamin D deficiency among tuberculosis patients by ethnic group and geographical region of birth: evidence from a diverse south London population.
    Eur Respir J. 2016;48:1507-1510.
    PubMed     Text format    


  118. ERKENS CG, Slump E, Verhagen M, Schimmel H, et al
    Risk of developing tuberculosis disease among persons diagnosed with latent tuberculosis infection in the Netherlands.
    Eur Respir J. 2016;48:1420-1428.
    PubMed     Text format     Abstract available


  119. RENDON A, Fuentes Z, Torres-Duque CA, Granado MD, et al
    Roadmap for tuberculosis elimination in Latin American and Caribbean countries: a strategic alliance.
    Eur Respir J. 2016;48:1282-1287.
    PubMed     Text format    


  120. SOTGIU G, Beer N, Aliberti S, Migliori GB, et al
    Fighting tuberculosis in the EU/EEA: towards the new European Union standards on tuberculosis care.
    Eur Respir J. 2016;48:1278-1281.
    PubMed     Text format    


    October 2016
  121. UPLEKAR M, Atre S, Wells WA, Weil D, et al
    Mandatory tuberculosis case notification in high tuberculosis-incidence countries: policy and practice.
    Eur Respir J. 2016 Oct 20. pii: ERJ-00956-2016. doi: 10.1183/13993003.00956-2016
    PubMed     Text format     Abstract available


  122. VAN ALTENA R, Akkerman OW, Alffenaar JC, Kerstjens HA, et al
    Shorter treatment for multidrug-resistant tuberculosis: the good, the bad and the ugly.
    Eur Respir J. 2016 Oct 6. pii: ERJ-01208-2016. doi: 10.1183/13993003.01208-2016.
    PubMed     Text format    


  123. LEE RS, Proulx JF, Menzies D, Behr MA, et al
    Progression to tuberculosis disease increases with multiple exposures.
    Eur Respir J. 2016 Oct 6. pii: ERJ-00893-2016. doi: 10.1183/13993003.00893-2016.
    PubMed     Text format     Abstract available


  124. DE VRIES G, van Rest J, Meijer W, Schimmel H, et al
    Tuberculosis screening yield of asylum seekers in Europe.
    Eur Respir J. 2016;48:1255-1256.
    PubMed     Text format    


  125. ARRAZOLA DE ONATE W, Weber L, Janssens K, Wanlin M, et al
    Tuberculosis screening yield of asylum seekers in Europe.
    Eur Respir J. 2016;48:1253-1254.
    PubMed     Text format    


    September 2016
  126. WINGFIELD T, Tovar MA, Huff D, Boccia D, et al
    The economic effects of supporting tuberculosis-affected households in Peru.
    Eur Respir J. 2016 Sep 22. pii: ERJ-00066-2016. doi: 10.1183/13993003.00066-2016
    PubMed     Text format     Abstract available


  127. SOTGIU G, Pontali E, Centis R, D'Ambrosio L, et al
    New anti-tuberculosis drugs for special populations: a difficult-to-address issue.
    Eur Respir J. 2016;48:957-8.
    PubMed     Text format    


  128. ZUUR MA, Akkerman OW, Davies Forsman L, Hu Y, et al
    Fixed-dose combination and therapeutic drug monitoring in tuberculosis: friend or foe?
    Eur Respir J. 2016 Sep 1. pii: ERJ-00833-2016. doi: 10.1183/13993003.00833-2016.
    PubMed     Text format    


  129. ANDERSON C, Anderson SR, Maguire H, Hayward AC, et al
    Tuberculosis in London: the convergence of clinical and social complexity.
    Eur Respir J. 2016 Sep 1. pii: ERJ-00749-2016. doi: 10.1183/13993003.00749-2016.
    PubMed     Text format    


  130. MITNICK CD, White RA, Lu C, Rodriguez CA, et al
    Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method.
    Eur Respir J. 2016 Sep 1. pii: ERJ-00462-2016. doi: 10.1183/13993003.00462-2016.
    PubMed     Text format     Abstract available


  131. SOTGIU G, Nahid P, Loddenkemper R, Abubakar I, et al
    The ERS-endorsed official ATS/CDC/IDSA clinical practice guidelines on treatment of drug-susceptible tuberculosis.
    Eur Respir J. 2016 Sep 1. pii: ERJ-01356-2016. doi: 10.1183/13993003.01356-2016.
    PubMed     Text format    


  132. SOTGIU G, Tiberi S, D'Ambrosio L, Centis R, et al
    Faster for less: the new "shorter" regimen for multidrug-resistant tuberculosis.
    Eur Respir J. 2016 Sep 1. pii: ERJ-01249-2016. doi: 10.1183/13993003.01249-2016.
    PubMed     Text format    


  133. SMIRNOVA PA, Turkova A, Nikishova EI, Seddon JA, et al
    Multidrug-resistant tuberculosis in children in northwest Russia: an observational cohort study.
    Eur Respir J. 2016 Sep 1. pii: ERJ-00354-2016. doi: 10.1183/13993003.00354-2016.
    PubMed     Text format    


    August 2016
  134. STURKENBOOM MG, Akkerman OW, van Altena R, de Lange WC, et al
    Dosage of isoniazid and rifampicin poorly predicts drug exposure in tuberculosis patients.
    Eur Respir J. 2016 Aug 4. pii: ERJ-00986-2016. doi: 10.1183/13993003.00986-2016.
    PubMed     Text format    


  135. DARA M, Solovic I, Sotgiu G, D'Ambrosio L, et al
    Tuberculosis care among refugees arriving in Europe: a ERS/WHO Europe Region survey of current practices.
    Eur Respir J. 2016 Aug 4. pii: ERJ-00840-2016. doi: 10.1183/13993003.00840-2016.
    PubMed     Text format     Abstract available


    July 2016
  136. BLOK N, van den Boom M, Erkens C, Dara M, et al
    Variation in policy and practice of adolescent tuberculosis management in the WHO European Region.
    Eur Respir J. 2016 Jul 28. pii: ERJ-00704-2016. doi: 10.1183/13993003.00704-2016
    PubMed     Text format    


  137. ALBERT H, Nathavitharana RR, Isaacs C, Pai M, et al
    Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better?
    Eur Respir J. 2016 Jul 13. pii: ERJ-00543-2016. doi: 10.1183/13993003.00543-2016
    PubMed     Text format     Abstract available


  138. MARX FM, Floyd S, Ayles H, Godfrey-Faussett P, et al
    High burden of prevalent tuberculosis among previously treated people in Southern Africa suggests potential for targeted control interventions.
    Eur Respir J. 2016 Jul 7. pii: ERJ-00716-2016. doi: 10.1183/13993003.00716-2016.
    PubMed     Text format    



  139. ERJ July Podcast: tuberculosis prevention and control in refugees.
    Eur Respir J. 2016;48:E67.
    PubMed     Text format    


  140. DE VRIES G, van Rest J, Meijer W, Wolters B, et al
    Preventing and controlling tuberculosis among refugees in Europe: more needed for high-risk populations.
    Eur Respir J. 2016;48:274-6.
    PubMed     Text format    


  141. DARA M, Solovic I, Goletti D, Sotgiu G, et al
    Preventing and controlling tuberculosis among refugees in Europe: more is needed.
    Eur Respir J. 2016;48:272-4.
    PubMed     Text format    


    June 2016
  142. TADOLINI M, Garcia-Prats AJ, D'Ambrosio L, Hewison C, et al
    Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges.
    Eur Respir J. 2016 Jun 23. pii: ERJ-00705-2016. doi: 10.1183/13993003.00705-2016
    PubMed     Text format    


  143. GUGLIELMETTI L, Le Du D, Veziris N, Caumes E, et al
    Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis?
    Eur Respir J. 2016 Jun 23. pii: ERJ-00411-2016. doi: 10.1183/13993003.00411-2016
    PubMed     Text format    


  144. TADOLINI M, Lingtsang RD, Tiberi S, Enwerem M, et al
    First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline.
    Eur Respir J. 2016 Jun 10. pii: ERJ-00637-2016. doi: 10.1183/13993003.00637-2016
    PubMed     Text format    


  145. ZUUR MA, Akkerman OW, Touw DJ, van der Werf TS, et al
    Dried blood spots can help decrease the burden on patients dually infected with multidrug-resistant tuberculosis and HIV.
    Eur Respir J. 2016 Jun 10. pii: ERJ-00599-2016. doi: 10.1183/13993003.00599-2016
    PubMed     Text format    


  146. EDWARDS TL, Valverde E, Mulder C, Cox C, et al
    Pouched rats as detectors of tuberculosis: comparison to concentrated smear microscopy.
    Eur Respir J. 2016 Jun 10. pii: ERJ-00264-2016. doi: 10.1183/13993003.00264-2016
    PubMed     Text format    


    May 2016
  147. GAO L, Bai L, Liu J, Lu W, et al
    Annual risk of tuberculosis infection in rural China: a population-based prospective study.
    Eur Respir J. 2016 May 26. pii: ERJ-00235-2016. doi: 10.1183/13993003.00235-2016
    PubMed     Text format     Abstract available


  148. CORDEIRO DA COSTA J, Oliveira O, Baia L, Gaio R, et al
    Prevalence and factors associated with diabetes mellitus among tuberculosis patients: a nationwide cohort.
    Eur Respir J. 2016 May 12. pii: ERJ-00254-2016. doi: 10.1183/13993003.00254-2016
    PubMed     Text format    


  149. DOBLER CC, Martin A, Marks GB
    Benefit of treatment of latent tuberculosis infection in individual patients.
    Eur Respir J. 2016;47:1594-5.
    PubMed     Text format    


  150. FLUEGGE K
    Benefit of treatment of latent tuberculosis infection in individual patients.
    Eur Respir J. 2016;47:1592-4.
    PubMed     Text format    


  151. GETAHUN H, Matteelli A, Abubakar I, Hauer B, et al
    Advancing global programmatic management of latent tuberculosis infection for at risk populations.
    Eur Respir J. 2016;47:1327-30.
    PubMed     Text format    


    April 2016
  152. VAN HEST R, de Vries G
    Active tuberculosis case-finding among drug users and homeless persons: after the outbreak.
    Eur Respir J. 2016 Apr 21. pii: ERJ-00284-2016. doi: 10.1183/13993003.00284-2016
    PubMed     Text format    


  153. BLANKLEY S, Graham CM, Levin J, Turner J, et al
    A 380-gene meta-signature of active tuberculosis compared with healthy controls.
    Eur Respir J. 2016 Apr 13. pii: ERJ-02121-2015. doi: 10.1183/13993003.02121-2015
    PubMed     Text format    


  154. BOLHUIS MS, Tiberi S, Sotgiu G, De Lorenzo S, et al
    Is there still room for therapeutic drug monitoring of linezolid in patients with tuberculosis?
    Eur Respir J. 2016;47:1288-90.
    PubMed     Text format    


  155. CATTANEO D, Gervasoni C, Clementi E
    Is there still room for therapeutic drug monitoring of linezolid in patients with tuberculosis?
    Eur Respir J. 2016;47:1287-8.
    PubMed     Text format    


  156. TIBERI S, Payen MC, Sotgiu G, D'Ambrosio L, et al
    Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.
    Eur Respir J. 2016;47:1235-43.
    PubMed     Text format     Abstract available


    March 2016
  157. AKKERMAN OW, de Lange WC, Scholvinck EH, Wolters B, et al
    Implementing tuberculosis entry screening for asylum seekers: the Groningen experience.
    Eur Respir J. 2016 Mar 23. pii: ERJ-00112-2016. doi: 10.1183/13993003.00112-2016
    PubMed     Text format    


  158. DARA M, Solovic I, Sotgiu G, D'Ambrosio L, et al
    Statement of the European Respiratory Society and the European Region of the International Union Against Tuberculosis and Lung Disease: call for urgent actions to ensure access to early diagnosis and care of tuberculosis among refugees.
    Eur Respir J. 2016 Mar 23. pii: ERJ-00377-2016. doi: 10.1183/13993003.00377-2016
    PubMed     Text format    


  159. GHIMIRE S, Bolhuis MS, Sturkenboom MG, Akkerman OW, et al
    Incorporating therapeutic drug monitoring into the World Health Organization hierarchy of tuberculosis diagnostics.
    Eur Respir J. 2016 Mar 17. pii: ERJ-00040-2016. doi: 10.1183/13993003.00040-2016
    PubMed     Text format    


  160. DE VRIES G, van Rest J, Meijer W, Wolters B, et al
    Low yield of screening asylum seekers from countries with a tuberculosis incidence of <50 per 100 000 population.
    Eur Respir J. 2016 Mar 10. pii: ERJ-00099-2016. doi: 10.1183/13993003.00099-2016
    PubMed     Text format    


  161. PAI M, Sotgiu G
    Diagnostics for latent TB infection: incremental, not transformative progress.
    Eur Respir J. 2016;47:704-6.
    PubMed     Text format    


  162. KOLAHIAN S, Oz HH, Zhou B, Griessinger CM, et al
    The emerging role of myeloid-derived suppressor cells in lung diseases.
    Eur Respir J. 2016;47:967-77.
    PubMed     Text format     Abstract available


    February 2016
  163. ERKENS CG, Slump E, Verhagen M, Schimmel H, et al
    Monitoring latent tuberculosis infection diagnosis and management in the Netherlands.
    Eur Respir J. 2016 Feb 25. pii: ERJ-01397-2015. doi: 10.1183/13993003.01397-2015
    PubMed     Text format     Abstract available


  164. PANG Y, Du J, Qin ZZ, Greenwald Z, et al
    An overview on tuberculosis-specific hospitals in China in 2009: results of a national survey.
    Eur Respir J. 2016 Feb 25. pii: ERJ-01854-2015. doi: 10.1183/13993003.01854-2015
    PubMed     Text format    


  165. FATTORINI L, Mustazzolu A, Borroni E, Piccaro G, et al
    Tuberculosis in migrants from 106 countries in Italy, 2008-2014.
    Eur Respir J. 2016 Feb 4. pii: ERJ-01844-2015. doi: 10.1183/13993003.01844-2015.
    PubMed     Text format    


  166. VENKATRAMAN N, King T, Bell D, Woltmann G, et al
    High levels of neurological involvement but low mortality in miliary tuberculosis: a 6-year case-series from the UK.
    Eur Respir J. 2016 Feb 4. pii: ERJ-01958-2015. doi: 10.1183/13993003.01958-2015.
    PubMed     Text format    


  167. MATTEELLI A, Lonnroth K, Mosca D, Getahun H, et al
    Cameroon's multidrug-resistant tuberculosis treatment programme jeopardised by cross-border migration.
    Eur Respir J. 2016;47:686-8.
    PubMed     Text format    


  168. PONTALI E, Sotgiu G, D'Ambrosio L, Centis R, et al
    Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence.
    Eur Respir J. 2016;47:394-402.
    PubMed     Text format    


  169. NOESKE J, Foe JL, Kuaban C
    Cameroon's MDR-TB treatment programme jeopardised by cross-border migration.
    Eur Respir J. 2016;47:684-6.
    PubMed     Text format    


  170. VAN DER BURGT EP, Sturkenboom MG, Bolhuis MS, Akkerman OW, et al
    End TB with precision treatment!
    Eur Respir J. 2016;47:680-2.
    PubMed     Text format    


    January 2016
  171. VAN RIJN SP, van Altena R, Akkerman OW, van Soolingen D, et al
    Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis.
    Eur Respir J. 2016 Jan 7. pii: ERJ-01654-2015. doi: 10.1183/13993003.01654-2015.
    PubMed     Text format     Abstract available


  172. AMARAL AF, Coton S, Kato B, Tan WC, et al
    Lung function defects in treated pulmonary tuberculosis patients.
    Eur Respir J. 2016;47:352-3.
    PubMed     Text format    


  173. AGGARWAL D, Ku V, Janmeja AK
    Lung function defects in treated pulmonary tuberculosis patients.
    Eur Respir J. 2016;47:351-2.
    PubMed     Text format    


  174. BRIGDEN G, du Cros P, Wong S
    Barriers to new drug development in respiratory disease.
    Eur Respir J. 2016;47:356-7.
    PubMed     Text format    


  175. PINETON DE CHAMBRUN M, Lemiale V, Azoulay E
    Lung positron emission tomography with FDG in patients with haematological malignancies and acute respiratory failure.
    Eur Respir J. 2016;47:324-7.
    PubMed     Text format    


    December 2015
  176. LOPEZ-VARELA E, Augusto OJ, Guerra L, Respeito D, et al
    Low paediatric tuberculosis case detection rate in Southern Mozambique.
    Eur Respir J. 2015 Dec 23. pii: ERJ-01454-2015. doi: 10.1183/13993003.01454-2015
    PubMed     Text format    


  177. HOFF ST, Peter JG, Theron G, Pascoe M, et al
    Sensitivity of C-Tb: a novel RD-1-specific skin test for the diagnosis of tuberculosis infection.
    Eur Respir J. 2015 Dec 17. pii: ERJ-01464-2015. doi: 10.1183/13993003.01464-2015
    PubMed     Text format     Abstract available


  178. DIEL R, Nienhaus A, Hillemann D, Richter E, et al
    Cost-benefit analysis of Xpert(R) MTB/RIF for tuberculosis suspects in German hospitals.
    Eur Respir J. 2015 Dec 2. pii: ERJ-01333-2015. doi: 10.1183/13993003.01333-2015.
    PubMed     Text format     Abstract available


  179. SIWENDU S, Mitchell M, Diacon AH, von Groote-Bidlingmaier F, et al
    Recruitment challenges for clinical trials with novel regimens for drug-resistant tuberculosis.
    Eur Respir J. 2015 Dec 2. pii: ERJ-01330-2015. doi: 10.1183/13993003.01330-2015.
    PubMed     Text format    


  180. PYM AS, Diacon AH, Tang SJ, Conradie F, et al
    Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis.
    Eur Respir J. 2015 Dec 2. pii: ERJ-00724-2015. doi: 10.1183/13993003.00724-2015.
    PubMed     Text format     Abstract available


  181. CHANG EW, Page AL, Bonnet M
    Light-emitting diode fluorescence microscopy for tuberculosis diagnosis: a meta-analysis.
    Eur Respir J. 2015 Dec 2. pii: ERJ-00978-2015. doi: 10.1183/13993003.00978-2015.
    PubMed     Text format     Abstract available



  182. ERJ December Podcast: Management of latent Mycobacterium tuberculosis infection.
    Eur Respir J. 2015;46:E60.
    PubMed     Text format    


  183. HUGHES J, Isaakidis P, Andries A, Mansoor H, et al
    Linezolid in drug-resistant tuberculosis: haste makes waste.
    Eur Respir J. 2015;46:1844-6.
    PubMed     Text format    


  184. BHUNIYA S, Mohapatra PR, Panigrahi MK, Behera P, et al
    Linezolid in drug-resistant tuberculosis: haste makes waste.
    Eur Respir J. 2015;46:1843-4.
    PubMed     Text format    


  185. SOTGIU G, Cirillo DM, Miotto P, Centis R, et al
    Accelerating tuberculosis elimination in low-incidence settings: the role of genomics.
    Eur Respir J. 2015;46:1841-3.
    PubMed     Text format    


  186. GUTHRIE JL, Gardy JL
    Accelerating tuberculosis elimination in low-incidence settings: the role of genomics.
    Eur Respir J. 2015;46:1840-1.
    PubMed     Text format    


  187. MATTEELLI A, Lonnroth K, Getahun H, Falzon D, et al
    Numbers needed to treat to prevent tuberculosis.
    Eur Respir J. 2015;46:1838-9.
    PubMed     Text format    


  188. SESTER M, van Crevel R, Leth Fv, Lange C, et al
    Numbers needed to treat to prevent tuberculosis.
    Eur Respir J. 2015;46:1836-8.
    PubMed     Text format    


    November 2015
  189. TIBERI S, D'Ambrosio L, De Lorenzo S, Viggiani P, et al
    Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience.
    Eur Respir J. 2015 Nov 19. pii: ERJ-01278-2015. doi: 10.1183/13993003.01278-2015
    PubMed     Text format    


  190. LOSI M, Knights AJ, Mariani F, Altieri AM, et al
    QuantiFERON-TB performance enhanced by novel Mycobacterium tuberculosis-specific antigens.
    Eur Respir J. 2015 Nov 19. pii: ERJ-01015-2015. doi: 10.1183/13993003.01015-2015
    PubMed     Text format    


  191. TIBERI S, D'Ambrosio L, De Lorenzo S, Viggiani P, et al
    Tuberculosis elimination, patients' lives and rational use of new drugs: revisited.
    Eur Respir J. 2015 Nov 5. pii: ERJ-01297-2015. doi: 10.1183/13993003.01297-2015.
    PubMed     Text format    


    October 2015
  192. FIEBIG L, Hauer B, Brodhun B, Altmann D, et al
    Tuberculosis in Germany: a declining trend coming to an end?
    Eur Respir J. 2015 Oct 22. pii: ERJ-01410-2015. doi: 10.1183/13993003.01410-2015
    PubMed     Text format    


  193. TOGUN TO, Egere U, Gomez MP, Sillah AK, et al
    No added value of interferon-gamma release to a prediction model for childhood tuberculosis.
    Eur Respir J. 2015 Oct 22. pii: ERJ-00890-2015. doi: 10.1183/13993003.00890-2015
    PubMed     Text format     Abstract available


  194. WOLFSON LJ, Gibbert J, Wirth D, Diel R, et al
    Cost-effectiveness of incorporating bedaquiline into a treatment regimen for multidrug-resistant/extensively drug-resistant tuberculosis in Germany.
    Eur Respir J. 2015 Oct 22. pii: ERJ-00811-2015. doi: 10.1183/13993003.00811-2015
    PubMed     Text format    


  195. TICONA E, Huaman MA, Huaroto LM, Burgos M, et al
    Tuberculosis screening using ability to provide sputum in an endemic emergency department.
    Eur Respir J. 2015 Oct 22. pii: ERJ-00877-2015. doi: 10.1183/13993003.00877-2015
    PubMed     Text format    


    September 2015
  196. DOBLER CC, Martin A, Marks GB
    Benefit of treatment of latent tuberculosis infection in individual patients.
    Eur Respir J. 2015 Sep 24. pii: ERJ-00577-2015. doi: 10.1183/13993003.00577-2015
    PubMed     Text format     Abstract available


  197. PANDE T, Pai M, Khan FA, Denkinger CM, et al
    Use of chest radiography in the 22 highest tuberculosis burden countries.
    Eur Respir J. 2015 Sep 24. pii: ERJ-01064-2015. doi: 10.1183/13993003.01064-2015
    PubMed     Text format    


  198. GETAHUN H, Matteelli A, Abubakar I, Aziz MA, et al
    Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries.
    Eur Respir J. 2015 Sep 24. pii: ERJ-01245-2015. doi: 10.1183/13993003.01245-2015
    PubMed     Text format     Abstract available


  199. WINTERS N, Butler-Laporte G, Menzies D
    Efficacy and safety of World Health Organization group 5 drugs for multidrug-resistant tuberculosis treatment.
    Eur Respir J. 2015 Sep 17. pii: ERJ-00649-2015. doi: 10.1183/13993003.00649-2015
    PubMed     Text format     Abstract available


    August 2015
  200. RAKOTOSAMIMANANA N, Richard V, Raharimanga V, Gicquel B, et al
    Biomarkers for risk of developing active tuberculosis in contacts of TB patients: a prospective cohort study.
    Eur Respir J. 2015 Aug 6. pii: ERJ-00263-2015. doi: 10.1183/13993003.00263-2015.
    PubMed     Text format     Abstract available



  201. "Contact investigation for tuberculosis: a systematic review and meta-analysis." Gregory J. Fox, Simone E. Barry, Warwick J. Britton and Guy B. Marks. Eur Respir J 2013; 41: 140-156.
    Eur Respir J. 2015;46:578.
    PubMed     Text format    


  202. FALZON D, Raviglione M, Bel EH, Gratziou C, et al
    The role of eHealth and mHealth in tuberculosis and tobacco control: a WHO/ERS consultation.
    Eur Respir J. 2015;46:307-11.
    PubMed     Text format    


  203. NATHAVITHARANA RR, Friedland JS
    A tale of two global emergencies: tuberculosis control efforts can learn from the Ebola outbreak.
    Eur Respir J. 2015;46:293-6.
    PubMed     Text format    


    July 2015
  204. KRIEGER D, Vesenbeckh S, Schonfeld N, Bettermann G, et al
    Mefloquine as a potential drug against multidrug-resistant tuberculosis.
    Eur Respir J. 2015 Jul 23. pii: ERJ-00321-2015. doi: 10.1183/13993003.00321-2015
    PubMed     Text format    


  205. BOLHUIS MS, Tiberi S, Sotgiu G, De Lorenzo S, et al
    Linezolid tolerability in multidrug-resistant tuberculosis: a retrospective study.
    Eur Respir J. 2015 Jul 9. pii: ERJ-00606-2015. doi: 10.1183/13993003.00606-2015.
    PubMed     Text format    


    June 2015
  206. KROIDL I, Clowes P, Reither K, Mtafya B, et al
    Performance of urine lipoarabinomannan assays for paediatric tuberculosis in Tanzania.
    Eur Respir J. 2015 Jun 25. pii: ERJ-00033-2015. doi: 10.1183/09031936.00003315.
    PubMed     Text format     Abstract available


  207. AMARAL AF, Coton S, Kato B, Tan WC, et al
    Tuberculosis associates with both airflow obstruction and low lung function: BOLD results.
    Eur Respir J. 2015 Jun 25. pii: ERJ-02325-2014. doi: 10.1183/13993003.02325-2014
    PubMed     Text format     Abstract available


  208. MORI T, Burhan E
    Supporting progress towards the post-2015 targets and regional tuberculosis elimination: a statement of intent from the third meeting of the Asian TB Experts Community.
    Eur Respir J. 2015;45:1760-2.
    PubMed     Text format    


    May 2015
  209. VAN DER PAARDT AF, Wilffert B, Akkerman OW, de Lange WC, et al
    Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis.
    Eur Respir J. 2015 May 28. pii: ERJ-01470-2014.
    PubMed     Text format     Abstract available


  210. GILLINI L, Centis R, D'Ambrosio L, Fedele A, et al
    Is Europe ready to reach tuberculosis elimination? An outbreak report from Southern Italy.
    Eur Respir J. 2015 May 28. pii: ERJ-00127-2015.
    PubMed     Text format    


    March 2015
  211. VANDEN DRIESSCHE K, Patel MR, Mbonze N, Tabala M, et al
    Effect of smoking history on outcome of patients diagnosed with TB and HIV.
    Eur Respir J. 2015;45:839-42.
    PubMed     Text format    


    January 2015
  212. TANG S, Yao L, Hao X, Zhang X, et al
    Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China.
    Eur Respir J. 2015;45:161-70.
    PubMed     Text format     Abstract available


  213. YU MC, Chen HY, Chien SH, Jou R, et al
    An integrated MDR-TB management programme results in favourable outcomes in northern Taiwan.
    Eur Respir J. 2015;45:272-5.
    PubMed     Text format    


    October 2014
  214. DENKINGER CM, Pai M
    Using cerebrospinal fluid for the diagnosis of tuberculous meningitis with GeneXpert.
    Eur Respir J. 2014;44:1095-6.
    PubMed     Text format    


  215. LUO RF, Gaur RL, Banaei N
    Using cerebrospinal fluid for the diagnosis of tuberculous meningitis with GeneXpert.
    Eur Respir J. 2014;44:1094-5.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Tuberculosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: